Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson

Sales to Customers

Sales to Customers %Chg

Sales to Customers Common Size

Cost of Products Sold

Cost of Products Sold %Chg

Cost of Products Sold Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Selling, Marketing and Administrative Expenses

Selling, Marketing and Administrative Expenses %Chg

Selling, Marketing and Administrative Expenses Common Size

Research and Development Expense

Research and Development Expense %Chg

Research and Development Expense Common Size

In-Process Research and Development Impairments

In-Process Research and Development Impairments %Chg

In-Process Research and Development Impairments Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Interest Expense, Net of Portion Capitalized

Interest Expense, Net of Portion Capitalized %Chg

Interest Expense, Net of Portion Capitalized Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Restructuring

Restructuring %Chg

Restructuring Common Size

Earnings Before Provision for Taxes on Income

Earnings Before Provision for Taxes on Income %Chg

Earnings Before Provision for Taxes on Income Common Size

Provision for Taxes on Income

Provision for Taxes on Income %Chg

Provision for Taxes on Income Common Size

Net Earnings from Continuing Operations

Net Earnings from Continuing Operations %Chg

Net Earnings from Continuing Operations Common Size

Net Earnings from Discontinued Operations, Net of Tax

Net Earnings from Discontinued Operations, Net of Tax %Chg

Net Earnings from Discontinued Operations, Net of Tax Common Size

Net Earnings

Net Earnings %Chg

Net Earnings Common Size

Continuing Operations - Basic

Continuing Operations - Basic %Chg

Continuing Operations - Basic Common Size

Discontinued Operations - Basic

Discontinued Operations - Basic %Chg

Discontinued Operations - Basic Common Size

Basic

Basic %Chg

Basic Common Size

Net Earnings per Share from Continuing Operations

Net Earnings per Share from Continuing Operations %Chg

Net Earnings per Share from Continuing Operations Common Size

Net Earnings per Share from Discontinued Operations

Net Earnings per Share from Discontinued Operations %Chg

Net Earnings per Share from Discontinued Operations Common Size

Diluted

Diluted %Chg

Diluted Common Size

Cash Dividends per Share

Cash Dividends per Share %Chg

Cash Dividends per Share Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Discontinued Operations

Net Income Attributable to Discontinued Operations %Chg

Net Income Attributable to Discontinued Operations Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	92,149	90,627	89,331	88,821	87,696	86,576
Total Revenues %Chg	5.1%	4.7%	4.3%	4.3%	4.8%	5.1%
Sales to Customers
Cost of Sales	—	—	—	27,471	—	26,784
Cost of Products Sold
Gross Profit	92,149	90,627	89,331	61,350	87,696	59,792
Gross Profit
Gross Profit Margin	100%	100%	100%	69.1%	100%	69.1%
Selling, General & Administrative Expenses	—	—	—	22,869	—	22,148
Selling, Marketing and Administrative Expenses
Research & Development Expenses	—	—	—	17,232	—	14,909
Research and Development Expense
Other Operating Expenses	186	164	87	445	248	365
In-Process Research and Development Impairments
Restructuring
Operating Profit	91,963	90,463	89,244	20,804	87,448	22,370
Operating Margin	99.8%	99.8%	99.9%	23.4%	99.7%	25.8%
Interest and Investment Income	—	—	—	1,332	—	—
Interest Income
Interest Expense	—	—	—	-755	—	—
Interest Expense, Net of Portion Capitalized
Non-Operating Income	—	—	—	-4,694	—	-3,135
Other Expense, Net
Total Non-Operating Income	—	—	—	-4,117	—	-3,135
Income Before Provision for Income Taxes	91,963	90,463	89,244	16,687	87,448	19,505
Earnings Before Provision for Taxes on Income
Provision for Income Taxes	—	—	—	2,621	—	3,123
Provision for Taxes on Income
Consolidated Net Income	91,963	90,463	89,244	14,066	87,448	16,382
Net Earnings from Continuing Operations
Net Income Attributable to Discontinued Operations	—	—	—	—	—	—
Net Earnings from Discontinued Operations, Net of Tax
Net Income Attributable to Common Shareholders	91,963	90,463	89,244	14,066	87,448	38,018
Net Earnings
Basic EPS	10.4	9.4	9.1	5.8	6.1	15.3
Diluted EPS	10.4	9.4	9	5.8	6.1	15.2
Basic Weighted Average Shares Outstanding	2,412.2	2,412	2,412.1	2,407.3	2,413.2	2,442.2
Total Shares Outstanding	2,406.2	2,406.8	2,405.6	2,406.9	2,407.3	2,407
Diluted Weighted Average Shares Outstanding	2,424.7	2,424.5	2,425.2	2,429.4	2,427.7	2,458.1
EBITDA	99,351	97,920	96,540	28,143	94,734	29,639
Effective Tax Rate	—	—	—	15.7%	—	16%